Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715912 | 0.81 | MGAM (0.36) | TET2HSD17B10CYP2D6 | |
| SCHEMBL7938516 | 0.81 | TET2 (0.36) | TET2ALOX15HSD17B10TET3TET1 | |
| SCHEMBL22615873 | 0.80 | CYP2D6 (0.40) | CYP2D6 | |
| SCHEMBL22615680 | 0.80 | PAM (0.30) | — | |
| SCHEMBL7715916 | 0.79 | LDHA (0.35) | CYP2D6 | |
| SCHEMBL7083288 | 0.78 | TSHR (0.41) | TET2ALOX15HSD17B10CYP2D6TET3 | |
| SCHEMBL16609377 | 0.74 | TET2 (0.38) | TET2ALOX15HSD17B10TET3TET1 | |
| SCHEMBL22615798 | 0.74 | CYP2D6 (0.38) | CYP2D6 | |
| SCHEMBL4838871 | 0.74 | TET2 (0.42) | TET2ALOX15HSD17B10CYP2D6TET3 | |
| SCHEMBL18825733 | 0.73 | CYP19A1 (0.40) | TET2ALOX15HSD17B10TET3TET1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-3962602-B1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2022-08-25 | — | — | US | disclosed |
| EP-3962602-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962888-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| CN-113825740-A | Itaconic acid derivatives and their use in the treatment of inflammatory diseases or diseases associated with adverse immune reactions | 西特瑞治疗有限公司 | 2021-12-21 | — | — | CN | disclosed |
| WO-2020222010-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020222011-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | IL1R1, IL1B, IL1A | TET2 919/4885ALOX15 56/4885HSD17B10 224/4885 |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | IL1R1, IL1B, IL1A | TET2 919/4885ALOX15 56/4885HSD17B10 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.